Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of diabetes mellitus (Type 1 or Type 2)~* Hemoglobin A1c (HbA1c) of less than or equal to (≤)10% within 2 months prior to Day 1~* Macular thickening secondary to diabetic macular edema (DME) involving the center of the fovea~* Decreased visual acuity attributable primarily to DME~* Ability and willingness to undertake all scheduled visits and assessments~* For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods that result in a failure rate of \<1% per year during the treatment period and for at least 3 months after the final dose of study treatment~Exclusion Criteria:~* Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1~* Uncontrolled blood pressure, defined as a systolic value greater than (\>)180 millimeters of mercury (mmHg) and/or a diastolic value \>100 mmHg while a patient is at rest~* Currently pregnant or breastfeeding, or intend to become pregnant during the study~* Treatment with panretinal photocoagulation or macular laser within 3 months prior to Day 1 to the study eye~* Any intraocular or periocular corticosteroid treatment within 6 months prior to Day 1 to the study eye~* Prior administration of IVT faricimab in either eye~* Active intraocular or periocular infection or active intraocular inflammation in the study eye~* Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye~* Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye~* Other protocol-specified inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Faricimab 6 mg Q8W (Type: EXPERIMENTAL): Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.
- B: Faricimab 6 mg PTI (Type: EXPERIMENTAL): Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.
- C: Aflibercept 2 mg Q8W (Type: ACTIVE_COMPARATOR): Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.

Based on this trial design, predict the completion outcome and termination type (if applicable).